Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Abstract

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients. Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States

“…Without chemotherapy, many patients succumb to AML within a few months. 5 For these reasons, the National Comprehensive Cancer Network guidelines in AML 6 and the European LeukemiaNet expert panel guidelines 7 recommend initial use of chemotherapy in patients with AML.…”

Treatment-related acute myeloid leukemia in a chronic lymphocytic leukemia patient: role of fludarabine?

“…National Comprehensive Cancer Network (NCCN) AML guideline 2014 recommends enrollment in a clinical trial or allogeneic stem-cell transplantation for highrisk AML including therapy-related AML (NCCN. org) [O'Donnell et al 2014]. …”

A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features

“…All consecutive patients who met the standards and received DAC+IA or IA regimen were included without selection. Patients underwent prognostic stratification and response estimation in accordance with the 2018 National Comprehensive Cancer Network (NCCN) guidelines . Finally, a total of 108 patients were enrolled.…”